Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced the launch in Japan of its percutaneous analgesic and anti-inflammatory drug Loxonin® Gel 1% (generic name, loxoprofen sodium hydrate; approval for manufacture and marketing, June 9, 2010; drug price listing, September 24...
ArQule, Inc. (Nasdaq: ARQL) and Daiichi Sankyo Co., Ltd. (TSE 4568) announced that they will move forward with a Phase 3 clinical trial of ARQ 197, a small molecule inhibitor of the c-Met receptor tyrosine kinase, in patients with non-small cell lung cancer (NSCLC). In connection with this...